Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fexapotide - Nymox Pharmaceutical

Drug Profile

Fexapotide - Nymox Pharmaceutical

Alternative Names: Fexapotide triflutate; NX-1207; REC-0482

Latest Information Update: 24 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nymox Pharmaceutical Corporation
  • Developer Nymox Pharmaceutical Corporation; Recordati
  • Class Antineoplastics; Proteins
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Benign prostatic hyperplasia
  • Phase III Prostate cancer
  • Discontinued Liver cancer

Most Recent Events

  • 22 Oct 2019 Nymox has extended patent protection for fexapotide in USA and European countries untill 2037
  • 09 Oct 2018 Updated long-term efficacy data from the phase IIb NX03-0040 trial in Prostate cancer released by Nymox Pharmaceutical
  • 03 Oct 2018 Phase-III clinical trials in Prostate cancer in USA (Intraprostatic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top